Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study

Patients must meet the following criteria for study entry:: * Signed Informed Consent Form * Age ≥ 18 years at enrollment * At least one prior line of systemic (Stage III-IV) follicular lymphoma therapy * Relapsed or refractory to front-line anti-lymphoma therapy; refractory is defined as: tumor shrinkage of less than 50% or disease progression after 4 cycles of standard regimen chemotherapy; response to standard regimen chemotherapy, relapse within 24 months; 2 or more relapses, meeting one of the above criteria as refractory lymphoma. * Conditional treatment with obinutuzumab in combination with lenalidomide Exclusion Criteria: * Patients currently participating or planning to participate in any interventional clinical trial * Any other reason that, in the opinion of the investigator, makes the patient unsuitable for this study